Current Combination Therapy News and Events

Current Combination Therapy News and Events, Combination Therapy News Articles.
Sort By: Most Relevant | Most Viewed
Page 1 of 25 | 1000 Results
Study shows new treatment pathway to prevent and treat endometrial cancer recurrence
In a new study led by Yale Cancer Center, researchers demonstrate sex hormones and insulin growth factors are associated with recurrence risk of endometrial cancer. (2021-02-23)

Structured exercise program, not testosterone therapy improved men's artery health
A 12-week, structured exercise program improved artery health and function in men ages 50 to 70 years old who had low to normal testosterone levels before the program began. Adding testosterone therapy to exercise or testosterone therapy alone did not improve artery health or function. (2021-02-22)

New therapeutic approach may help treat age-related macular degeneration effectively
Runt-related transcription factor 1 (RUNX1) has been linked to retinal neovascularization and the development of abnormal blood vessels, which result in vision loss in diabetic retinopathy. Now, scientists have found that RUNX1 inhibition presents a new therapeutic approach in the treatment of age-related macular degeneration (AMD), which is the leading cause of blindness in the elderly worldwide. Their results are reported in The American Journal of Pathology, published by Elsevier. (2021-02-22)

Improving immunotherapies for blood cancers: real-time exploration in the tumor
Monoclonal antibodies are part of the therapeutic arsenal for eliminating cancer cells. Some make use of the immune system to act and belong to a class of treatment called ''immunotherapies.'' But how do these antibodies function within the tumor? And how can we hope to improve their efficacy? Using innovative in vivo imaging approaches, scientists from the Institut Pasteur and Inserm visualized in real time how anti-CD20 antibodies, used to treat B-cell lymphoma, guide the immune system to attack tumor cells. (2021-02-21)

Neoadjuvant combination immunotherapy improves outcomes for early stage non-small cell lung cancer
The first randomized Phase II clinical trial to report on single and combined neoadjuvant immune checkpoint inhibitor therapy in stage I-III non-small cell lung cancer (NSCLC) found combination therapy produced a significant clinical benefit. (2021-02-18)

UCLA study finds combination therapy suppresses pancreatic tumor growth in mice
UCLA Jonsson Comprehensive Cancer Center researchers have uncovered a potential new way to target pancreatic tumors that express high intratumoral interferon signaling (IFN). (2021-02-18)

Physical therapy after c-section improves outcomes
Women who received physical therapy after undergoing a cesarean section had significantly improved outcomes compared to those who did not according to a new study from University of Missouri Health Care. (2021-02-17)

Vets' depression, social support & psychological resilience play role in later well being
Veterans who experienced the combination of low depression, high social support and high psychological resilience as they left military service were most likely to report high well-being a year later. (2021-02-17)

Friends fur life help build skills for life
A new UBC Okanagan study finds children not only reap the benefits of working with therapy dogs-they enjoy it too. (2021-02-17)

Psychotherapy for panic disorder shows positive long-term effects
Psychotherapy for panic disorder produces good results, and the effects are lasting. That is the result from a large long-term study from Lund University in Sweden. Two years after treatment were 70 per cent of the patients clearly improved and 45 per cent were remitted. (2021-02-16)

Molecular imaging determines effectiveness of novel metastatic breast cancer treatment
Molecular imaging can successfully predict response to a novel treatment for ER-positive, HER2-negative metastatic breast cancer patients who are resistant to hormonal therapy. According to research published in the February issue of The Journal of Nuclear Medicine, positron emission tomography (PET) imaging using an imaging agent called 18F-fluoroestradiol can help to determine which patients could benefit from treatments that could spare them from unnecessary chemotherapy. (2021-02-16)

Combination treatment for common glioma type shows promise in mice
Gliomas are common brain tumors that comprise about one third of all cancers of the nervous system. In a study funded by the National Institutes of Health (NIH), researchers tested a novel combination treatment approach on mice with tumors with characteristics similar to human astrocytomas and found tumor regression in 60 percent of the mice treated. These encouraging results could be the first step toward developing a treatment for this type of brain cancer. (2021-02-16)

Immunotherapy -- targeted drug combination improves survival in advanced kidney cancer
Patients with advanced kidney cancer, who received a targeted drug combined with a checkpoint-blocker immunotherapy agent had longer survival than patients treated with the standard targeted drug, said an investigator from Dana-Farber Cancer Institute, reporting results from a phase 3 clinical trial. (2021-02-13)

Researchers identify potential revolutionary new drug treatment for fatal childhood cancer
Research paper published reveals potential revolutionary drug combination that could become an effective treatment for DIPG. (2021-02-12)

Oncotarget: Combination of copanlisib with cetuximab improves tumor response
''These data support further investigation of PI3K inhibition in HNSCC and suggests gene expression patterns associated with PI3K signaling'' (2021-02-10)

Brain tumor study reveals surprising gene deletion and method to overcome drug resistance
Experts at Cincinnati Children's report success at averting drug resistance in a subtype of brain tumors called glioblastomas. Importantly, the research indicates that the approach may also work in other cancers, such as melanoma, that exhibit a similar pathway of drug resistance. (2021-02-10)

Combination therapy with radiation shows promise in treating glioblastoma
In a study of mice, researchers at the UCLA Jonsson Comprehensive Cancer Center have identified a new approach that combines an anti-psychotic drug, a statin used to lower high cholesterol levels, and radiation to improve the overall survival in mice with glioblastoma (2021-02-09)

Joint radionuclide therapy-immunotherapy approach effective in prostate cancer model
A combination of radionuclide therapy and immunotherapy has proven successful in slowing the progression of prostate cancer and increasing survival time, according to new research published in the February issue of The Journal of Nuclear Medicine. The results of the murine study indicate that radionuclide therapy promotes prostate cancer immunogenicity, provoking a cellular response that makes the tumors more receptive to immunotherapy. (2021-02-08)

Findings of study comparing analgesics in acute post-trauma pain
The combination of a high?dose NSAID with paracetamol does not increase the analgesic effect compared to paracetamol alone. Researchers also found that paracetamol alone is superior to high?dose NSAID alone for posttraumatic extremity pain. (2021-02-08)

New combination therapy offers chance of healing hepatitis B
Around 260 million people, more than three percent of the global population, are chronically infected with the hepatitis B virus (HBV); in the long term, this often leads to complications such as liver cirrhosis and liver cancer. A cure is not yet possible with the available medication. Scientists at the German Center for Infection Research (DZIF) and the University Hospital Eppendorf (UKE) have now investigated a new combination therapy that has proven highly effective in their infection model. (2021-02-04)

Researchers assess cognitive impairment in patients with breast cancer
A recent analysis of published studies in Psycho-Oncology estimates that one-quarter of adults with breast cancer have cognitive impairment before starting therapy. (2021-02-03)

Imaging identifies breast cancer patients unlikely to benefit from hormone therapy
Hormone therapy can be very effective for so-called estrogen receptor-positive breast cancer. But it only works for a little more than half of women who receive the treatment. In a small study, researchers at Washington University School of Medicine in St. Louis found that women whose tumors did not respond to a one-day estrogen challenge did not benefit from hormone therapy. The findings could help doctors choose treatments most likely to help their patients. (2021-02-02)

Gene mutations linked to worse outcomes from leukemia in Hispanic and Latino children
A combination of genetic mutations may explain the higher incidence of and poorer outcomes from pediatric leukemia in Hispanic and Latino children, according to Penn State College of Medicine researchers. They said a novel therapeutic drug combination - as well as testing for these mutations - may help address the disparity. (2021-02-02)

Novel therapy-resistance mechanism promoting the growth of breast cancer brain metastasis
SORLA is a protein trafficking receptor that has been mainly studied in neurons, but it also plays a role in cancer cells. Professor Johanna Ivaska's research group at Turku Bioscience observed that SORLA functionally contributes to the most reported therapy-resistant mechanism by which the cell-surface receptor HER3 counteracts HER2 targeting therapy in HER2-positive cancers. Removing SORLA from cancer cells sensitized anti-HER2 resistant breast cancer brain metastasis to targeted therapy. (2021-01-29)

Sotorasib provides durable clinical benefit for patients with NSCLC and KRAS mutations
In the phase II CodeBreak 100 trial, sotorasib provided durable clinical benefit with a favorable safety profile in patients with pretreated non-small cell lung cancer (NSCLC) and who harbor KRAS p.G12C mutations, validating CodeBreak 100's phase I results, according to research presented today at the International Association for the Study of Lung Cancer World Conference on Lung Cancer. (2021-01-28)

Gut microbiota reveals whether drug therapies work in inflammatory bowel diseases
A study recently completed at the University of Helsinki indicates that the gut microbiota of patients suffering from inflammatory gastrointestinal disorders can be used to predict whether they will benefit from expensive therapies. The study also confirms the key role of therapies that have a beneficial effect on the gut microbiota in inflammatory bowel diseases. (2021-01-26)

Oncotarget: Improved therapeutic efficacy of unmodified anti-tumor antibodies
The Oncotarget findings suggest that MEKi induced an increased expression of tumor-associated antigens, which in combination with anti-tumor antibodies, generated a robust adaptive anti-tumor response that was sustained by immune checkpoint inhibition therapy. (2021-01-25)

University of Cincinnati research unveils possible new combo therapy for head and neck cancer
Researchers at the University of Cincinnati have tested a new combination therapy in animal models to see if they could find a way to make an already effective treatment even better. Since they're using a Food and Drug Administration-approved drug to do it, this could help people sooner than later. (2021-01-22)

Investigational combo therapy shows benefit for TP53 mutant MDS and AML patients
Moffitt Cancer Center is leading a national, multicenter clinical trial investigating a new therapy option for this group of patients. It builds upon the standard of care therapy, combining eprenetapopt (APR-246) with the chemotherapy azacitidine. Results of the phase 1b/2 trial to determine the safety, recommended dose and efficacy of the combination therapy were published in the Journal of Clinical Oncology. (2021-01-21)

New combination of immunotherapies shows great promise for treating lung cancer
McMaster University researchers have established in lab settings that a novel combination of two forms of immunotherapy can be highly effective for treating lung cancer, which causes more deaths than any other form of cancer. (2021-01-21)

Researchers uncover potentially promising therapeutic combination for renal cell carcinoma
Investigators have demonstrated that ACE2 expression is a good prognostic factor in RCC, that loss of ACE2 mediates resistance to classical treatments, and that in preclinical models, treatment with a drug that is downstream of ACE2 can improve tumor responses in RCC and significantly prolong survival. (2021-01-20)

Genome editing to treat human retinal degeneration
Gene editing therapies, including CRISPR-Cas systems, offer the potential to correct mutations causing inherited retinal degenerations, a leading cause of blindness. Technological advances in gene editing, continuing safety concerns, and strategies to overcome these challenges (2021-01-19)

Biodistribution of AAV gene transfer vectors in nonhuman primate
The biodistribution of adeno-associated virus (AAV) gene transfer vectors can be measured in nonhuman primates using a new method. The method quantifies whole-body and organ-specific AAV capsids from 1 to 72 hours after administration (2021-01-15)

UNH researchers discover new inhibitor drug combination for rare form of cancer
Researchers at the University of New Hampshire took the novel approach of targeting specific cell proteins that control DNA information using inhibitors, or drugs, that were effective in reducing the growth of the Waldenström macroglobulinemia cancer cells and when combined with a third drug were even more successful in killing the WM cancer cells which could lead to more treatment options. (2021-01-14)

New England Journal of Medicine publishes COVID-19 treatment trial results
In a multicenter study funded by the National Institutes of Health, a combination of two drugs, baricitinib and remdesivir, reduced time to recovery in hospitalized COVID-19 patients. The results from sites including UT Health San Antonio and University Health were published Dec. 11 in the New England Journal of Medicine. (2021-01-14)

Nanotechnology prevents premature birth in mouse studies
In a study in mice and human cells, Johns Hopkins Medicine researchers say that they have developed a tiny, yet effective method for preventing premature birth. (2021-01-13)

How anorexia nervosa alters body awareness
People with anorexia nervosa have a distorted relationship with the dimensions of their body. A study by the team at the Clinic for Psychosomatic Medicine and Psychotherapy at LWL University Hospital at Ruhr-Universität Bochum (RUB) has shown that, in addition to the conscious body image, what is known as the body schema - unconscious body awareness - is also distorted. It normally adapts to the current situation. (2021-01-12)

Treatment for chronic pain must address both physical and social pain
Physical pain and social pain may be more closely related than previously thought. Social pain, which typically results from interpersonal rejection or abuse, has been viewed as a non-medical response to external factors. However, recent research suggests that some physical and social stress responses may arise because of shared processing in the brain. (2021-01-12)

A prognostic Alzheimer's disease blood test in the symptom-free stage
Using a blood test, a German-Dutch research team has predicted the risk of Alzheimer's disease in people who were clinically diagnosed as not having Alzheimer's disease but who perceived themselves as cognitively impaired (Subjective Cognitive Declined, SCD). The researchers analyzed blood samples from an SCD cohort supervised at the Alzheimer Center Amsterdam. Using a test developed in Bochum, they identified all 22 subjects at study entry who developed Alzheimer's dementia, thus the clinical symptoms, within six years. (2021-01-06)

Ibrutinib with rituximab in previously untreated CLL: indication of added benefit over FCR
Ibrutinib with rituximab in previously untreated CLL: indication of added benefit over FCR. The new drug combination prolongs overall survival in patients in good general health. No study data are available for other patient groups. (2021-01-05)

Page 1 of 25 | 1000 Results
   First   Previous   Next      Last   
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.